Fuse Vectors

Executive Summary

Fuse Vectors is a Danish biotechnology company focused on overcoming key limitations of adeno-associated virus (AAV) vectors used in gene therapy. While AAVs are the leading platform for in vivo gene delivery due to their safety profile, they suffer from limited packaging capacity, high prevalence of neutralizing antibodies, and inefficiency in targeting specific tissues. Fuse Vectors is engineering next-generation AAV capsids with enhanced properties, such as improved transduction efficiency, reduced immunogenicity, and the ability to evade pre-existing immunity. Their proprietary platform aims to expand the therapeutic reach of AAV-based gene therapies to larger genes and more patient populations, including those previously excluded due to seroprevalence. The company was founded in 2021 and is headquartered in Copenhagen, Denmark, emerging from a strong ecosystem of life sciences innovation. While still at an early stage, Fuse Vectors' technology addresses critical bottlenecks in gene therapy, potentially enabling safer and more effective treatments for a wide range of genetic disorders.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for lead capsid variant in a mouse model70% success
• Q4 2026Series A financing round to advance platform and candidate development65% success
• TBDStrategic partnership with a larger gene therapy company for capsid licensing40% success